Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells.

@article{Singh2006PharmacoproteomicsO4,
  title={Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells.},
  author={Om Vir Singh and Neeraj Vij and Peter J Mogayzel and Cathy Jozwik and Harvey B Pollard and Pamela L Zeitlin},
  journal={Journal of proteome research},
  year={2006},
  volume={5 3},
  pages={562-71}
}
4-Phenylbutyrate (4-PBA) is an oral butyrate derivative that has recently been approved for treatment of urea cycle disorders and is under investigation in clinical trials of cancer, hemoglobinopathies, and cystic fibrosis (CF). We hypothesized that proteome profiling of IB3-1 cystic fibrosis bronchial epithelial cells treated with 4-PBA would identify butyrate-responsive cellular chaperones, protein processing enzymes, and cell trafficking molecules associated with the amelioration of the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…